Relmada Therapeutics, Inc. Banner Image

Relmada Therapeutics, Inc.

  • Ticker RLMD
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Relmada Therapeutics, Inc. Logo Image
  • 1-10 Employees
  • Based in New York City, New York
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonistsMore may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
4.8 / 5.0 (126)

Relmada Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 126 reviews.

Relmada Therapeutics, Inc.

Most Recent Annual Report

Relmada Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Relmada Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!